Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals Plc on July 8, 2014. The report discloses a specific intellectual property event regarding the Company's wholly owned subsidiary, Jazz Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory and intellectual property milestone rather than financial performance.
Material Changes and Events
- Patent Issuance: On July 8, 2014, the U.S. Patent and Trademark Office issued U.S. Patent No. 8,772,306 to the Company.
- Patent Subject: The patent is titled "Method of Administration of Gamma Hydroxybutyrate with Monocarboxylate Transporters."
- Product Application: The patent relates to the safe and effective use of Xyrem (sodium oxybate) oral solution. Specifically, it covers decreasing the dose of Xyrem in patients receiving a concomitant dose of divalproex sodium (valproate/valproic acid), as provided in the Xyrem label.
- Expiration Date: The patent is set to expire on March 15, 2033.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to submit this patent for listing in the U.S. Food and Drug Administration's "Orange Book" (Approved Drug Products With Therapeutic Equivalence Evaluations).
Risks and Uncertainties: The report contains forward-looking statements regarding the expected listing of the patent. The Company notes that actual results could differ materially due to risks associated with regulatory matters and the protection of intellectual property rights. The Company explicitly states it undertakes no duty to update these forward-looking statements.
Investor Verification Checklist
- Verify the successful listing of U.S. Patent No. 8,772,306 in the FDA Orange Book.
- Monitor the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, and subsequent filings for detailed "Risk Factors" regarding intellectual property.
- Confirm the patent expiration date of March 15, 2033, in official USPTO records.